Clinical trials
Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 6,142 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05681650RecruitingPhase 1/Phase 2
HER2-targeted CAR-T for HER2-positive advanced solid tumors
This trial tests a new immune-cell therapy (CAR-T) that targets a protein called HER2 in people with advanced or metastatic solid cancers. It may help shrink tumors and control the disease after standard treatments have failed or when there is no clear standard option.
Beijing, Beijing MunicipalityAges 18–75 - NCT05684965RecruitingPhase 1/Phase 2
Study drug for advanced solid cancers after standard treatments
This Phase 1/2 trial tests XTX301, a study treatment, in people with advanced solid tumors (cancers) that have already been treated and are not controlled by standard options. It may help if your cancer matches one of the study groups and you meet safety and test-tissue requirements.
Sacramento, CaliforniaAges 18 years+ - NCT05687682RecruitingPhase 1
AM-928 infusion safety study for advanced solid tumors
This Phase 1 trial tests how safe AM-928 is when given through an IV infusion to people with advanced solid cancers that can’t be removed by surgery and have stopped responding to standard treatments. It may help doctors learn the safest dose and whether the drug causes side effects worth watching.
TaipeiAges 18 years+ - NCT05690581RecruitingPhase 1
CM369 for advanced cancers with special immune marker in tumors
This Phase 1 study tests how safe and tolerable CM369 is in people with advanced solid tumors or blood cancers. It also looks at how the drug behaves in the body and whether it can help shrink or control cancer, especially when a tumor marker called CCR8 is present.
Guangzhou, GuangdongAges 18–75 - NCT05697926Recruiting
Personalized immune T-cell therapy study for head and neck cancer
This study focuses on testing a personalized immune therapy (made from your tumor-fighting T cells) for people with head and neck cancer. It may help patients whose cancer is new and untreated or whose cancer has come back or is not responding to standard options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05701527RecruitingPhase 1
EBC-129 for advanced solid tumors with limited treatment options
This Phase 1 study tests EBC-129, a new investigational treatment, in people with advanced solid tumors that cannot be fully removed and have limited or no good standard treatment options. The goal is to learn if the treatment is safe, find helpful dosing, and see signs it may slow the cancer.
Aurora, ColoradoAges 18 years+ - NCT05701709RecruitingPhase 1
First-in-human test for a new drug in advanced solid cancers
This Phase 1 study tests SHR-A2102, a new cancer medicine, in adults with advanced solid tumors. It mainly looks at safety and how the body handles the drug, and it may help if standard treatments are not working or are not an option.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05704530Recruiting
Liquid blood tests for early esophageal cancer
This trial studies how well “liquid biopsy” blood tests can work in people with newly diagnosed, operable esophageal cancer. It may help doctors monitor the cancer and guide treatment planning alongside standard care.
AntwerpAges 18 years+ - NCT05713903Recruiting
Compare keyhole versus open surgery for right colon cancer
This trial compares two surgical approaches—keyhole surgery versus open surgery—for right colon cancer. It aims to see which approach works better and is safer for patients needing planned (elective) tumor removal.
LarissaAges 18–90 - NCT05722275Recruiting
Predicting peritoneal spread in advanced stomach cancer
This trial uses CT scan images and a look inside the abdomen (laparoscopy) to predict whether advanced stomach cancer has spread to the lining of the abdomen (the peritoneum). It may help your care team better identify who already has peritoneal spread and who might not.
BeijingAges 18 years+ - NCT05725291RecruitingPhase 1
Early study drug for advanced cancers after other treatments
This Phase 1 trial tests AMT-116, an investigational medicine, in people with advanced solid cancers that can’t be removed by surgery and have gotten worse after standard treatment. It looks for the best safe dose and early signs the treatment may shrink tumors or slow growth.
Denver, ColoradoAges 18 years+ - NCT05726370RecruitingPhase 2
Pembrolizumab plus chemo before surgery for recurrent head and neck cancer
This Phase 2 trial tests whether giving pembrolizumab (an immune therapy) plus chemotherapy before curative surgery can improve outcomes for people with resectable, recurrent head and neck squamous cell cancer. It also studies how these treatments affect the tumor and immune response using required tissue and blood samples.
Boston, MassachusettsAges 18 years+ - NCT05727176RecruitingPhase 2
Futibatinib for advanced bile duct cancer with FGFR2 changes
This trial tests futibatinib, a targeted pill, in people with advanced (unresectable) or metastatic bile duct cancer that has an FGFR2 fusion or rearrangement. It may help shrink tumors after standard chemotherapy has stopped working.
La Jolla, CaliforniaAges 18 years+ - NCT05733416Recruiting
FDG PET/CT scan after unexplained stroke to find hidden cancer
This study checks whether doing an intensive scan using FDG PET/CT shortly after a “cryptogenic” (unexplained) ischemic stroke can uncover an underlying cause, such as cancer. If a hidden source is found earlier, it may help guide the next treatment steps.
Ottawa, OntarioAges 18 years+ - NCT05738616RecruitingPhase 3
Testing lenvatinib plus TACE and immunotherapy before liver surgery
This study tests whether a combination of the drug lenvatinib, a liver treatment called TACE, and the immunotherapy drug camrelizumab can shrink advanced hepatocellular carcinoma enough to make surgery (or “conversion resection”) possible. It may help some people live longer by improving the chance that the cancer can be removed.
Chengdu, SichuanAges 18–75 - NCT05742178Recruiting
Cancer screening outreach and help in select NYC neighborhoods
This study tests an outreach program that helps people who may be behind on cancer screenings get connected to the right care. It mainly aims to reduce missed screenings in specific Brooklyn and Bronx communities.
New York, New YorkAges 21–75 - NCT05745623RecruitingPhase 1/Phase 2
Testing an NTRK-fusion drug for advanced tumors
This Phase 1/2 study tests ICP-723, a medicine designed to treat cancers that have an NTRK gene fusion. It may help shrink tumors in people whose cancer test shows this specific genetic change and who haven’t taken an NTRK inhibitor before.
Guangzhou, GuangdongAges 2 years+ - NCT05749627Recruiting
Vaccine for advanced cancers using your tumor’s targets
This trial tests a personalized vaccine made from “neoantigens” (tumor-specific targets) to help your immune system fight advanced, inoperable solid tumors. It may be an option if standard treatment didn’t work or you stopped it and your health is strong enough for trial treatment.
Nanchang, JiangxiAges 18–70 - NCT05764720Recruiting
Personalized targeted radiation for borderline pancreatic cancer
This study tests a personalized form of stereotactic radiation therapy (high-precision radiation planned to fit your tumor) after you’ve had some chemotherapy. It aims to treat pancreatic tumors while limiting exposure to nearby healthy organs.
Birmingham, AlabamaAges 18 years+ - NCT05765851RecruitingPhase 1
HER2-targeting drug study for advanced solid tumors
This Phase 1 trial tests a combination of medicines (including DS-1103a) for people with advanced, hard-to-remove (unresectable) or metastatic solid tumors that have HER2 changes. Because it’s an early safety/dose study, it mainly aims to find the right dose and see how the tumor responds.
Sarasota, FloridaAges 18 years+ - NCT05773820RecruitingPhase 1/Phase 2
Testing WJB001 capsules for advanced solid tumors
This early-phase study tests whether WJB001 capsules can treat advanced solid tumors in adults whose cancer has progressed after standard treatment (or who cannot take standard treatment). It also studies side effects and whether the drug can work for certain tumor types and genetic markers.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05773937RecruitingPhase 1
Study drug for advanced solid tumors after prior treatments
This Phase 1 study tests 9MW2821 in people with advanced solid cancers that have grown despite earlier treatment. It aims to find the safest dose and learn how the drug works, and it may be an option if you can provide tumor tissue and meet key health criteria.
Beijing, Beijing MunicipalityAges 18–80 - NCT05777824RecruitingPhase 2
Testing treatment after head and neck cancer response to chemo-immunotherapy
This Phase 2 study looks at what treatment is best after you first receive chemotherapy plus immunotherapy, then have surgery for head and neck squamous cell cancer. It tries to use how your tumor responds (shown in lab tissue after treatment) to guide the next steps, which may improve outcomes.
Beijin, Beijing MunicipalityAges 18–75 - NCT05779917RecruitingPhase 1
CAR-T cells for cancers that have specific target proteins
This Phase 1 trial tests a customized immune therapy (CAR-T cells) for advanced cancers that have the proteins mesothelin, GPC3, and/or GUCY2C. It may help your body better recognize and kill cancer cells, but early-phase trials mainly focus on safety and learning how well the treatment works.
Guangzhou, GuangdongAges 18–75
Hear when a new Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 6,142 recruiting advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.